Clinical and laboratory evidence [36,40] suggests a possible use of hepcidin as a predictive marker for the response to the treatment with epoetin in patients with solid tumors (lung cancer, multiple myeloma, non-Hodgkin's lymphoma, mixed tumors). This evidence concerns the gene HAMP and AL amyloidosis.